SCHEMBL24314221

SCHEMBL24314221

N#Cc1ccc2cc(C(=O)N[S+]([O-])c3ccccc3-c3ccccc3)oc2c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 1/20 0.36
KCNH2 Q12809 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
NPC1 O15118 2/20 0.36
TP53 P04637 2/20 0.36
RAB9A P51151 2/20 0.36
PKM P14618 1/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
F2 P00734 1/20 0.36
PLG P00747 1/20 0.36
PLAU P00749 1/20 0.36
KLKB1 P03952 1/20 0.36
PRSS1 P07477 1/20 0.36
HPGD P15428 2/20 0.36
TSHR P16473 1/20 0.36
PGR P06401 4/20 0.36
MIF P14174 1/20 0.36
CSNK2A2 P19784 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22601061 0.85 CHRNA7 (0.40) SMN1; SMN2NPC1TP53RAB9APKM
SCHEMBL22601033 0.85 NPC1 (0.51) SMN1; SMN2NPC1TP53RAB9APKM
SCHEMBL22600839 0.84 RAB9A (0.41) SMN1; SMN2NPC1TP53RAB9APKM
SCHEMBL24314307 0.84 RAB9A (0.45) SMN1; SMN2NPC1TP53RAB9APKM
SCHEMBL24313789 0.84 NPC1 (0.43) SMN1; SMN2NPC1TP53RAB9APKM
SCHEMBL22601146 0.82 NPC1 (0.39) SMN1; SMN2NPC1TP53RAB9APKM
SCHEMBL24313970 0.82 ALDH1A1 (0.40) SMN1; SMN2NPC1TP53RAB9APKM
SCHEMBL24313952 0.82 NPC1 (0.43) SMN1; SMN2NPC1TP53RAB9APKM
SCHEMBL24313793 0.82 ALDH1A1 (0.42) SMN1; SMN2NPC1TP53RAB9APKM
SCHEMBL24313631 0.81 HDAC6 (0.40) SMN1; SMN2NPC1TP53RAB9APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022081842-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. (US) 2022-04-21 WO disclosed